Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2023 08:00 ET | Source: Benitec Biopharma Inc.

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

Benitec Biopharma, a genetic medicines company, releases updates on OPMD program and other corporate and financial updates.
September 21, 2023 08:00 ET | Source: Benitec Biopharma Inc.

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD...
August 11, 2023 13:00 ET | Source: Benitec Biopharma Inc.

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

HAYWARD, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
August 08, 2023 22:30 ET | Source: Benitec Biopharma Inc.

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

HAYWARD, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
July 25, 2023 13:00 ET | Source: Benitec Biopharma Inc.

Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023

HAYWARD, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
June 26, 2023 08:00 ET | Source: Benitec Biopharma Inc.

Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

HAYWARD, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
May 15, 2023 08:00 ET | Source: Benitec Biopharma Inc.

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

HAYWARD, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel...
May 08, 2023 08:05 ET | Source: Benitec Biopharma Inc.

Benitec Biopharma to Present at the OPMD International Conference

HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel...
May 08, 2023 08:00 ET | Source: Benitec Biopharma Inc.

Benitec Biopharma to Present at the JMP Securities Life Sciences Conference

HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel...
February 13, 2023 08:00 ET | Source: Benitec Biopharma Inc.

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

HAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel...